Omicron infection enhances Delta antibody immunity in vaccinated persons

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Omicron infection enhances Delta antibody immunity in vaccinated persons. / Khan, Khadija; Karim, Farina; Cele, Sandile; Reedoy, Kajal; San, James Emmanuel; Lustig, Gila; Tegally, Houriiyah; Rosenberg, Yuval; Bernstein, Mallory; Jule, Zesuliwe; Ganga, Yashica; Ngcobo, Nokuthula; Mazibuko, Matilda; Mthabela, Ntombifuthi; Mhlane, Zoey; Mbatha, Nikiwe; Miya, Yoliswa; Giandhari, Jennifer; Ramphal, Yajna; Naidoo, Taryn; Sivro, Aida; Samsunder, Natasha; Kharsany, Ayesha B.M.; Amoako, Daniel; Bhiman, Jinal N.; Manickchund, Nithendra; Abdool Karim, Quarraisha; Magula, Nombulelo; Abdool Karim, Salim S.; Gray, Glenda; Hanekom, Willem; von Gottberg, Anne; Harrichandparsad, Rohen; Herbst, Kobus; Jeena, Prakash; Khoza, Thandeka; Kløverpris, Henrik; Leslie, Alasdair; Madansein, Rajhmun; Marakalala, Mohlopheni; Moshabela, Mosa; Naidoo, Kogie; Ndhlovu, Zaza; Ndung’u, Thumbi; Nyamande, Kennedy; Patel, Vinod; Smit, Theresa; Steyn, Adrie; Wong, Emily; Milo, Ron; COMMIT-KZN Team.

In: Nature, Vol. 607, No. 7918, 2022, p. 356-359.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Khan, K, Karim, F, Cele, S, Reedoy, K, San, JE, Lustig, G, Tegally, H, Rosenberg, Y, Bernstein, M, Jule, Z, Ganga, Y, Ngcobo, N, Mazibuko, M, Mthabela, N, Mhlane, Z, Mbatha, N, Miya, Y, Giandhari, J, Ramphal, Y, Naidoo, T, Sivro, A, Samsunder, N, Kharsany, ABM, Amoako, D, Bhiman, JN, Manickchund, N, Abdool Karim, Q, Magula, N, Abdool Karim, SS, Gray, G, Hanekom, W, von Gottberg, A, Harrichandparsad, R, Herbst, K, Jeena, P, Khoza, T, Kløverpris, H, Leslie, A, Madansein, R, Marakalala, M, Moshabela, M, Naidoo, K, Ndhlovu, Z, Ndung’u, T, Nyamande, K, Patel, V, Smit, T, Steyn, A, Wong, E, Milo, R & COMMIT-KZN Team 2022, 'Omicron infection enhances Delta antibody immunity in vaccinated persons', Nature, vol. 607, no. 7918, pp. 356-359. https://doi.org/10.1038/s41586-022-04830-x

APA

Khan, K., Karim, F., Cele, S., Reedoy, K., San, J. E., Lustig, G., Tegally, H., Rosenberg, Y., Bernstein, M., Jule, Z., Ganga, Y., Ngcobo, N., Mazibuko, M., Mthabela, N., Mhlane, Z., Mbatha, N., Miya, Y., Giandhari, J., Ramphal, Y., ... COMMIT-KZN Team (2022). Omicron infection enhances Delta antibody immunity in vaccinated persons. Nature, 607(7918), 356-359. https://doi.org/10.1038/s41586-022-04830-x

Vancouver

Khan K, Karim F, Cele S, Reedoy K, San JE, Lustig G et al. Omicron infection enhances Delta antibody immunity in vaccinated persons. Nature. 2022;607(7918):356-359. https://doi.org/10.1038/s41586-022-04830-x

Author

Khan, Khadija ; Karim, Farina ; Cele, Sandile ; Reedoy, Kajal ; San, James Emmanuel ; Lustig, Gila ; Tegally, Houriiyah ; Rosenberg, Yuval ; Bernstein, Mallory ; Jule, Zesuliwe ; Ganga, Yashica ; Ngcobo, Nokuthula ; Mazibuko, Matilda ; Mthabela, Ntombifuthi ; Mhlane, Zoey ; Mbatha, Nikiwe ; Miya, Yoliswa ; Giandhari, Jennifer ; Ramphal, Yajna ; Naidoo, Taryn ; Sivro, Aida ; Samsunder, Natasha ; Kharsany, Ayesha B.M. ; Amoako, Daniel ; Bhiman, Jinal N. ; Manickchund, Nithendra ; Abdool Karim, Quarraisha ; Magula, Nombulelo ; Abdool Karim, Salim S. ; Gray, Glenda ; Hanekom, Willem ; von Gottberg, Anne ; Harrichandparsad, Rohen ; Herbst, Kobus ; Jeena, Prakash ; Khoza, Thandeka ; Kløverpris, Henrik ; Leslie, Alasdair ; Madansein, Rajhmun ; Marakalala, Mohlopheni ; Moshabela, Mosa ; Naidoo, Kogie ; Ndhlovu, Zaza ; Ndung’u, Thumbi ; Nyamande, Kennedy ; Patel, Vinod ; Smit, Theresa ; Steyn, Adrie ; Wong, Emily ; Milo, Ron ; COMMIT-KZN Team. / Omicron infection enhances Delta antibody immunity in vaccinated persons. In: Nature. 2022 ; Vol. 607, No. 7918. pp. 356-359.

Bibtex

@article{daa073e7a7574a80a5e990ec9f54d2fe,
title = "Omicron infection enhances Delta antibody immunity in vaccinated persons",
abstract = "The extent to which Omicron infection1–9, with or without previous vaccination, elicits protection against the previously dominant Delta (B.1.617.2) variant is unclear. Here we measured the neutralization capacity against variants of severe acute respiratory syndrome coronavirus 2 in 39 individuals in South Africa infected with the Omicron sublineage BA.1 starting at a median of 6 (interquartile range 3–9) days post symptom onset and continuing until last follow-up sample available, a median of 23 (interquartile range 19–27) days post symptoms to allow BA.1-elicited neutralizing immunity time to develop. Fifteen participants were vaccinated with Pfizer's BNT162b2 or Johnson & Johnson's Ad26.CoV2.S and had BA.1 breakthrough infections, and 24 were unvaccinated. BA.1 neutralization increased from a geometric mean 50% focus reduction neutralization test titre of 42 at enrolment to 575 at the last follow-up time point (13.6-fold) in vaccinated participants and from 46 to 272 (6.0-fold) in unvaccinated participants. Delta virus neutralization also increased, from 192 to 1,091 (5.7-fold) in vaccinated participants and from 28 to 91 (3.0-fold) in unvaccinated participants. At the last time point, unvaccinated individuals infected with BA.1 had low absolute levels of neutralization for the non-BA.1 viruses and 2.2-fold lower BA.1 neutralization, 12.0-fold lower Delta neutralization, 9.6-fold lower Beta variant neutralization, 17.9-fold lower ancestral virus neutralization and 4.8-fold lower Omicron sublineage BA.2 neutralization relative to vaccinated individuals infected with BA.1. These results indicate that hybrid immunity formed by vaccination and Omicron BA.1 infection should be protective against Delta and other variants. By contrast, infection with Omicron BA.1 alone offers limited cross-protection despite moderate enhancement.",
author = "Khadija Khan and Farina Karim and Sandile Cele and Kajal Reedoy and San, {James Emmanuel} and Gila Lustig and Houriiyah Tegally and Yuval Rosenberg and Mallory Bernstein and Zesuliwe Jule and Yashica Ganga and Nokuthula Ngcobo and Matilda Mazibuko and Ntombifuthi Mthabela and Zoey Mhlane and Nikiwe Mbatha and Yoliswa Miya and Jennifer Giandhari and Yajna Ramphal and Taryn Naidoo and Aida Sivro and Natasha Samsunder and Kharsany, {Ayesha B.M.} and Daniel Amoako and Bhiman, {Jinal N.} and Nithendra Manickchund and {Abdool Karim}, Quarraisha and Nombulelo Magula and {Abdool Karim}, {Salim S.} and Glenda Gray and Willem Hanekom and {von Gottberg}, Anne and Rohen Harrichandparsad and Kobus Herbst and Prakash Jeena and Thandeka Khoza and Henrik Kl{\o}verpris and Alasdair Leslie and Rajhmun Madansein and Mohlopheni Marakalala and Mosa Moshabela and Kogie Naidoo and Zaza Ndhlovu and Thumbi Ndung{\textquoteright}u and Kennedy Nyamande and Vinod Patel and Theresa Smit and Adrie Steyn and Emily Wong and Ron Milo and {COMMIT-KZN Team}",
note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
doi = "10.1038/s41586-022-04830-x",
language = "English",
volume = "607",
pages = "356--359",
journal = "Nature",
issn = "0028-0836",
publisher = "nature publishing group",
number = "7918",

}

RIS

TY - JOUR

T1 - Omicron infection enhances Delta antibody immunity in vaccinated persons

AU - Khan, Khadija

AU - Karim, Farina

AU - Cele, Sandile

AU - Reedoy, Kajal

AU - San, James Emmanuel

AU - Lustig, Gila

AU - Tegally, Houriiyah

AU - Rosenberg, Yuval

AU - Bernstein, Mallory

AU - Jule, Zesuliwe

AU - Ganga, Yashica

AU - Ngcobo, Nokuthula

AU - Mazibuko, Matilda

AU - Mthabela, Ntombifuthi

AU - Mhlane, Zoey

AU - Mbatha, Nikiwe

AU - Miya, Yoliswa

AU - Giandhari, Jennifer

AU - Ramphal, Yajna

AU - Naidoo, Taryn

AU - Sivro, Aida

AU - Samsunder, Natasha

AU - Kharsany, Ayesha B.M.

AU - Amoako, Daniel

AU - Bhiman, Jinal N.

AU - Manickchund, Nithendra

AU - Abdool Karim, Quarraisha

AU - Magula, Nombulelo

AU - Abdool Karim, Salim S.

AU - Gray, Glenda

AU - Hanekom, Willem

AU - von Gottberg, Anne

AU - Harrichandparsad, Rohen

AU - Herbst, Kobus

AU - Jeena, Prakash

AU - Khoza, Thandeka

AU - Kløverpris, Henrik

AU - Leslie, Alasdair

AU - Madansein, Rajhmun

AU - Marakalala, Mohlopheni

AU - Moshabela, Mosa

AU - Naidoo, Kogie

AU - Ndhlovu, Zaza

AU - Ndung’u, Thumbi

AU - Nyamande, Kennedy

AU - Patel, Vinod

AU - Smit, Theresa

AU - Steyn, Adrie

AU - Wong, Emily

AU - Milo, Ron

AU - COMMIT-KZN Team

N1 - Publisher Copyright: © 2022, The Author(s).

PY - 2022

Y1 - 2022

N2 - The extent to which Omicron infection1–9, with or without previous vaccination, elicits protection against the previously dominant Delta (B.1.617.2) variant is unclear. Here we measured the neutralization capacity against variants of severe acute respiratory syndrome coronavirus 2 in 39 individuals in South Africa infected with the Omicron sublineage BA.1 starting at a median of 6 (interquartile range 3–9) days post symptom onset and continuing until last follow-up sample available, a median of 23 (interquartile range 19–27) days post symptoms to allow BA.1-elicited neutralizing immunity time to develop. Fifteen participants were vaccinated with Pfizer's BNT162b2 or Johnson & Johnson's Ad26.CoV2.S and had BA.1 breakthrough infections, and 24 were unvaccinated. BA.1 neutralization increased from a geometric mean 50% focus reduction neutralization test titre of 42 at enrolment to 575 at the last follow-up time point (13.6-fold) in vaccinated participants and from 46 to 272 (6.0-fold) in unvaccinated participants. Delta virus neutralization also increased, from 192 to 1,091 (5.7-fold) in vaccinated participants and from 28 to 91 (3.0-fold) in unvaccinated participants. At the last time point, unvaccinated individuals infected with BA.1 had low absolute levels of neutralization for the non-BA.1 viruses and 2.2-fold lower BA.1 neutralization, 12.0-fold lower Delta neutralization, 9.6-fold lower Beta variant neutralization, 17.9-fold lower ancestral virus neutralization and 4.8-fold lower Omicron sublineage BA.2 neutralization relative to vaccinated individuals infected with BA.1. These results indicate that hybrid immunity formed by vaccination and Omicron BA.1 infection should be protective against Delta and other variants. By contrast, infection with Omicron BA.1 alone offers limited cross-protection despite moderate enhancement.

AB - The extent to which Omicron infection1–9, with or without previous vaccination, elicits protection against the previously dominant Delta (B.1.617.2) variant is unclear. Here we measured the neutralization capacity against variants of severe acute respiratory syndrome coronavirus 2 in 39 individuals in South Africa infected with the Omicron sublineage BA.1 starting at a median of 6 (interquartile range 3–9) days post symptom onset and continuing until last follow-up sample available, a median of 23 (interquartile range 19–27) days post symptoms to allow BA.1-elicited neutralizing immunity time to develop. Fifteen participants were vaccinated with Pfizer's BNT162b2 or Johnson & Johnson's Ad26.CoV2.S and had BA.1 breakthrough infections, and 24 were unvaccinated. BA.1 neutralization increased from a geometric mean 50% focus reduction neutralization test titre of 42 at enrolment to 575 at the last follow-up time point (13.6-fold) in vaccinated participants and from 46 to 272 (6.0-fold) in unvaccinated participants. Delta virus neutralization also increased, from 192 to 1,091 (5.7-fold) in vaccinated participants and from 28 to 91 (3.0-fold) in unvaccinated participants. At the last time point, unvaccinated individuals infected with BA.1 had low absolute levels of neutralization for the non-BA.1 viruses and 2.2-fold lower BA.1 neutralization, 12.0-fold lower Delta neutralization, 9.6-fold lower Beta variant neutralization, 17.9-fold lower ancestral virus neutralization and 4.8-fold lower Omicron sublineage BA.2 neutralization relative to vaccinated individuals infected with BA.1. These results indicate that hybrid immunity formed by vaccination and Omicron BA.1 infection should be protective against Delta and other variants. By contrast, infection with Omicron BA.1 alone offers limited cross-protection despite moderate enhancement.

U2 - 10.1038/s41586-022-04830-x

DO - 10.1038/s41586-022-04830-x

M3 - Journal article

C2 - 35523247

AN - SCOPUS:85133576140

VL - 607

SP - 356

EP - 359

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7918

ER -

ID: 317092739